

# 1 **Mechanistic insight into substrate processing and** 2 **allosteric inhibition of human p97**

3

4

5 Man Pan<sup>1#\*</sup>, Yuanyuan Yu<sup>1#</sup>, Huasong Ai<sup>2</sup>, Qingyun Zheng<sup>2</sup>, Yuan Xie<sup>1</sup>, Lei Liu<sup>2\*</sup>, Minglei Zhao<sup>1\*</sup>

6

7

8 <sup>1</sup> Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, IL  
9 60637, USA.

10 <sup>2</sup> Tsinghua-Peking Center for Life Sciences, Department of Chemistry, Tsinghua University,  
11 Beijing 100084, China.

12

13

14 #These authors contributed equally to the work.

15 \*Corresponding authors:

16 Minglei Zhao: [mlzhao@uchicago.edu](mailto:mlzhao@uchicago.edu)

17 Lei Liu: [lliu@mail.tsinghua.edu.cn](mailto:lliu@mail.tsinghua.edu.cn)

18 Man Pan: [panm@uchicago.edu](mailto:panm@uchicago.edu)

19

20

21 **ABSTRACT**

22 p97, also known as valosin-containing protein (VCP), processes ubiquitinated substrates and  
23 plays a central role in cellular protein homeostasis. Mutations in human p97 are associated with  
24 multisystem proteinopathy (MSP), a dominantly inherited degenerative disorder that can affect  
25 muscle, bone and the central nervous system. It is also a drug target for cancer therapy with  
26 various inhibitors developed over the past decade. Despite significant structural insights into the  
27 fungal homologue of p97, Cdc48, little is known about how human p97 processes its substrates  
28 and how the activity is allosterically affected by inhibitors. Here, we report a series of cryo-  
29 electron microscopy (cryo-EM) structures of substrate-engaged human p97 complex with  
30 resolutions ranging from 2.9 to 3.8 Å that captured “power stroke”-like motions of both the D1  
31 and D2 ATPase rings of p97. The structures elucidated how the unfolded substrate is engaged  
32 in the pore at atomic level. Critical conformational changes of the inter-subunit signaling (ISS)  
33 motifs were revealed, providing molecular insights into substrate translocation. Furthermore, we  
34 also determined cryo-EM structures of human p97 in complex with NMS-873, the most potent  
35 p97 inhibitor, at a resolution of 2.4 Å. The structures showed that NMS-873 binds at a cryptic  
36 groove in the D2 domain and interacts with the ISS motif, preventing its conformational change,  
37 thus blocking substrate translocation allosterically. Finally, using NMS-873 at a  
38 substoichiometric concentration, we captured a series of intermediate states, suggesting how  
39 the cofactor Npl4 coordinates with the D1 ring of p97 to initiate the translocation.

40

41 **Keywords**

42 **p97, NMS-873, single-particle cryo-EM, translocation, allosteric inhibition**

43

## 44 INTRODUCTION

45 p97 is a 500 kDa protein that belongs to the family of ATPases Associated with diverse  
46 cellular Activities (AAA)<sup>1-3</sup>. It undergoes repetitive ATP hydrolysis and conformational changes  
47 to extract ubiquitinated substrates from various cellular components, such as membranes,  
48 ribosomes, and chromatin<sup>4</sup>. p97 plays a central role in many cellular processes, including  
49 endoplasmic reticulum-associated degradation (ERAD), mitochondrial-associated degradation,  
50 chromatin-associated degradation, autophagy, and endosomal trafficking<sup>5</sup>. Mutations in human  
51 p97 have been found in multisystem proteinopathy (MSP), a dominantly inherited degenerative  
52 disorder that can affect muscle, bone and the central nervous system, that can manifest  
53 clinically as inclusion body myopathy with early-onset Paget disease and frontotemporal  
54 dementia (IBMPFD) and familial amyotrophic lateral sclerosis (ALS)<sup>6,7</sup>. Moreover, recent studies  
55 have also targeted p97 for the treatment of cancer and viral infections<sup>8,9</sup>.

56 p97 has two tandem AAA domains named D1 and D2 and an additional N domain at the  
57 N-terminus (**Fig. 1a**). This protein functions as a homomeric hexamer, with twelve copies of  
58 ATPase domains organized into two rings<sup>10</sup>. Crystal structures of full-length p97 were  
59 determined more than a decade ago<sup>11,12</sup>. High-resolution single-particle cryo-electron  
60 microscopy (cryo-EM) structures have also been reported<sup>13,14</sup>. However, all the structures of p97  
61 determined thus far adopt a sixfold symmetric conformation, providing limited information  
62 regarding the mechanism since almost all AAA proteins, including close homologues of p97,  
63 break symmetry when engaged with substrates<sup>15-17</sup>. Recent cryo-EM studies of Cdc48, the  
64 yeast homolog of p97, in complex with either *in vivo*<sup>18</sup> or *in vitro*<sup>19</sup> substrates provided crucial  
65 insight into the working states. However, with medium resolution (3.7 Å to 4.2 Å) and limited  
66 conformational states, critical mechanistic questions, such as how the AAA domains in two rings  
67 coordinate to achieve translocation, remain to be answered. It is also not clear whether human  
68 p97 shares the same mechanism as its yeast homologue. In addition, owing to its biomedical  
69 importance, many small-molecule inhibitors of p97 have been developed in the past

70 decade<sup>8,20,21</sup>. Little is known regarding the allosteric inhibition mechanism due to the lack of a  
71 p97 structure in a working state, which is of considerable biological and clinical interest.

72 In this study, starting from a fully assembled p97 complex with the cofactor Npl4/Ufd1  
73 and a substrate, we triggered ATP hydrolysis and determined a series of substrate-engaged  
74 p97 structures with resolutions ranging from 2.9 to 3.8 Å using single-particle cryo-EM. The  
75 structures captured “power stroke”-like motions of both the D1 and D2 rings of p97 and  
76 elucidated how the two rings coordinate to achieve translocation through the pore loops,  
77 intersubunit signaling (ISS) motifs, and N- and C-terminal tails. We further determined the cryo-  
78 EM structures of p97 in the presence of NMS-873, an allosteric noncompetitive inhibitor<sup>21</sup>, at a  
79 resolution of 2.4 Å and uncovered its inhibition mechanism. It is worth noting that NMS-873 has  
80 been shown to be active in tumor cell lines and IBMPFD patient fibroblasts<sup>21,22</sup>. More  
81 interestingly, low nanomolar concentrations of NMS-873 was recently reported to inhibit the  
82 replication of several viruses, including severe acute respiratory syndrome coronavirus 2  
83 (SARS-CoV-2) and influenza virus, through its inhibition on p97<sup>23-25</sup>. Finally, using NMS-873 at a  
84 substoichiometric concentration, we captured a series of intermediate states, suggesting how  
85 p97 coordinates with its cofactor Npl4 to initiate substrate translocation. Taken together, our  
86 results established a comprehensive understanding of substrate processing and allosteric  
87 inhibition of human p97.

88

## 89 RESULTS

### 90 Capture the working states of human p97

91 First, we assembled complexes of p97 from recombinantly overexpressed components  
92 without introducing additional ATP. Two mutations, A232E and E578Q, were introduced into the  
93 human p97 construct to stabilize the complex as previously described<sup>26</sup>. The A232E mutation is  
94 found in MSP patients and is known as an activating mutant with its N domains locked in the “up  
95 conformation”<sup>27</sup>. E578Q is a mutation in the Walker B motif of the D2 domain that slows  
96 substrate unfolding<sup>19,28</sup>. Combined, the two mutations decreased but maintained the unfolding  
97 activity of p97 (**Extended Data Fig. 1a**) and minimized the conformational heterogeneity  
98 resulting from the N domains. All the structural work in this study used the p97 (A232E/E578Q)  
99 mutant and Npl4/Ufd1 as the cofactors. For substrates, either polyubiquitinated Ub-Eos (Ub<sub>n</sub>-  
100 Eos) or K48-linked hexa-ubiquitin (Ub<sub>6</sub>) was used. The assembled complex, named p97-  
101 Npl4/Ufd1-Ub<sub>n</sub>-Eos or p97-Npl4/Ufd1-Ub<sub>6</sub>, eluted as single peaks in the size-exclusion  
102 chromatograms (**Extended Data Fig. 1b and c**). To capture the working states of p97, ATP  
103 hydrolysis was triggered by adding 5 mM ATP to the purified complexes followed by incubation  
104 at room temperature for 5 minutes. To relieve the orientation preference, either CHAPSO or  
105 fluorinated octyl maltoside (FOM) was added immediately before sample vitrification (**Fig. 1b**).  
106 Three datasets, namely, p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-CHAPSO, p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-FOM, and  
107 p97-Npl4/Ufd1-Ub<sub>6</sub>-FOM, were collected, and a total of 9 different cryo-EM maps with  
108 resolutions ranging from 2.9 to 3.8 Å were reconstructed using single-particle analysis  
109 (**Extended Data Figs. 2-4, Extended Data Table 1**). Atomic models were built based on  
110 existing p97 structures (**Extended Data Table 2**). For well-resolved regions, individual residues  
111 were manually built into the density. For flexible regions, rigid body docking was used to fit  
112 individual secondary structure elements or subdomains (see Methods for details).

113

### 114 Open and closed states of the D2 ring

115 In the p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-CHAPSO dataset, two conformational states of the D2  
116 ring were resolved (**Fig. 1c and d**). In the open state (3.6 Å, **Fig. 1c**, corresponding to class 2 in  
117 **Extended Data Fig. 2**), all six D2 domains interacted with the substrate and formed an open,  
118 right-handed spiral, whereas in the closed state (3.1 Å, **Fig. 1d**, corresponding to class 1 in  
119 **Extended Data Fig. 2**), the bottom D2 domain (termed chain F) detached from the substrate  
120 and shifted up to interact with the top D2 domain (termed chain E), closing the gap of the spiral  
121 in the open state. Only five D2 domains (chains A-E) interacted with the substrate in the closed  
122 state. The two states suggested a “power stroke”-like motion of the D2 domain (**Supplemental**  
123 **Movie 1**). Compared to the same complex structure in the presence of ATP $\gamma$ S that was  
124 previously published<sup>26</sup> (PDB ID: 7JY5), there was a relative 20 degree rotation of the D2 ring to  
125 the D1 ring in both states (**Fig. 1e and Extended Data Fig. 5a**). A superimposition of the two  
126 states showed that the D2 domain immediately above chain F (chain A) also shifted up from the  
127 open state to the closed state (**Extended Data Fig. 6a and Supplemental Movie 1**). The  
128 particles in the open state were significantly less than those in the closed state (13% vs. 70%),  
129 suggesting that the open state is relatively transient. A third class was resolved from the 3D  
130 classification (3.8 Å, class 3 in **Extended Data Fig. 2**), with better resolved density for the  
131 cofactor Npl4 but otherwise the same conformation as the closed state.

132

### 133 **Conformational changes in the D1 ring**

134 In the p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-FOM dataset, three conformational states of the D1 ring  
135 were resolved (**Extended Data Fig. 3**). All the D2 rings were in the same conformation as the  
136 closed state described above. Using the same naming convention, we discovered from the  
137 superimposed structures that chain A shifted up slightly from class 1 (3.6 Å) to class 2 (3.4 Å)  
138 and much further from class 2 to class 3 (3.0 Å) (**Extended Data Fig. 7a**). No open spiral  
139 conformation similar to the open state of the D2 ring was observed for the D1 ring, although a  
140 right-handed spiral was still formed by chains B-F. The three states of the D1 ring also

141 suggested a “power stroke”-like motion despite the differences from the D2 ring (**Supplemental**  
142 **Movie 2**). It is worth noting that no conformational changes in the D1 ring were observed for the  
143 p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-CHAPSO dataset. The conformation of the D1 ring in the open and  
144 closed states was very similar to class 3 of the p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-FOM dataset (see  
145 Discussion).

146

### 147 **Sequential but asynchronous hydrolysis in D1 and D2 rings**

148 The resolutions of the maps allowed us to build atomic models and identify the  
149 nucleotides in most nucleotide binding sites (**Extended Data Figs. 6d and 7d**). For the less well  
150 resolved chains A and F, the identity of the nucleotides could not be determined with certainty,  
151 but the density of a nucleotide was clearly visible (**Extended Data Figs. 6d and 7d**). All  
152 nucleotide binding sites were occupied, suggesting that the nucleotide exchange might be very  
153 fast. When superimposing all the AAA domains within the same ring, two major conformations  
154 were observed: one with a larger angle between the  $\alpha/\beta$  and the  $\alpha$  subdomain, potentially  
155 corresponding to an ATP binding conformation, and the other with a smaller angle between the  
156  $\alpha/\beta$  and the  $\alpha$  subdomain, potentially corresponding to an ADP binding conformation (**Extended**  
157 **Data Figs. 6c and 7c**). Such binary conformations have been observed for N-ethylmaleimide  
158 sensitive factor (NSF), a close homologue of human p97<sup>17</sup>.

159 When focusing on the well-resolved sites, we discovered a new compact ATP binding  
160 mode in both the D1 and D2 rings involving a previously defined ISS motif<sup>29</sup>. Specifically, the  
161 ISS motif changed from a helical conformation to a triangular loop that inserted into the  
162 neighboring nucleotide binding site (**Fig. 1e and f**). L335 in the D1 domain and M611 in the D2  
163 domain are the key residues interacting with the hydrophobic residues in the Walker B motifs of  
164 the neighboring subunits (**Fig. 1f**). As a result, ATP is coordinated by three more residues than  
165 the ATP<sub>γ</sub>S-bound structure (PDB ID: 7JY5), including one additional arginine finger residue  
166 (R362 in D1 and R638 in D2), an aspartic acid from the ISS motif (D333 in D1 and D609 in D2),

167 and a basic residue following the Walker A motif (R256 in D1 and K529 in D2) (**Fig. 1f**). This  
168 binding mode was observed only when ATP was engaged and only for two to four consecutive  
169 binding sites in both rings (**Fig. 1e, Extended Data Figs. 6b and 7b**). We hypothesize that this  
170 tight binding mode results from rotational compression in ATPase rings essential for substrate  
171 translocation. For ATP hydrolysis to occur, the ISS motif needs to be retracted. For example,  
172 the ISS motif in the D2 domain of chain A retracted in the closed state (not in the open state)  
173 since the neighboring D2 domain in chain B is the next subunit to undergo ATP hydrolysis (**Fig.**  
174 **1e and Extended Data Fig. 6b**).

175 Another unexpected observation is that the hydrolysis in the D1 and D2 rings is not in  
176 sync, which means that at a given time, the D1 and D2 domains of the same chain may engage  
177 different nucleotides. If viewed from the top, hydrolysis propagates counterclockwise in both  
178 ATPase rings, with the D1 ring one or two subunits ahead of the D2 ring (**Fig. 1e**). This feature  
179 is unique for human p97 and has not been observed for other type II AAA proteins, including  
180 yeast Cdc48.

181

## 182 **Interactions between the pore loops and the substrate**

183 In all six maps discussed above, we observed the density corresponding to a  
184 translocating peptide going through the central pore of p97 (**Fig. 2a**). A continuous extended  
185 peptide could be modeled into the density. The peptide went through the pore from the N-  
186 terminus (bottom in **Fig. 2a**) to the C-terminus (top in **Fig. 2a**), as the other direction fit much  
187 worse into the density. This directionality of translocating peptide is consistent with that of  
188 Cdc48<sup>19,30</sup>. The density corresponding to the side chains was averaged, and polyalanine was  
189 modeled.

190 In general, the density of the translocating peptide in the D2 ring was better than that in  
191 the D1 ring. Three residues in pore loop-I (PL-I) of the D2 domain, namely, M550, W551, and  
192 F552, interacted with the peptide like a “pitching grip” (**Fig. 2a**). Each PL-I formed two hydrogen



193 bonds with the nitrogen and carbonyl oxygen of one residue in the translocating peptide through  
194 the carbonyl oxygen of M550 and nitrogen of F552. Every other residue in the translocating  
195 peptide was hydrogen bonded by a PL-I so 12 residues were engaged with six PL-I in the D2  
196 ring, which formed a spiral in the open state, with chain F at the bottom and chain E at the top  
197 (**Fig. 2a**). In the closed state, the PL-I of chain F detached from the translocating peptide. The  
198 remaining five PL-I formed the spiral in a very similar way except for the side chain of M550 in  
199 chain A (now the bottom chain), which was pointing downwards and would not allow an  
200 additional PL-I to engage (**Fig. 2a inset**). In both the open and closed states, the density of five  
201 pore loop-II (PL-II) in the D2 ring was resolved (chains A to E) but at lower resolution (**Fig. 2a**  
202 **inset**). PL-II in the D2 ring did not form hydrogen bonds with the translocating peptide and likely  
203 played a less important role in translocation. We mutated the residues of PL-I and PL-II and  
204 performed the substrate unfolding assay<sup>1,26,31</sup>. Indeed, the PL-I mutation (W551A/F552A)  
205 abolished the unfolding activity, whereas the PL-II mutation (I590A/D592A) showed no effect  
206 (**Fig. 2d**). A closer examination revealed that R599 was  $\pi$ -stacked with F552 of PL-I (**Fig. 2b**).  
207 This interaction might be critical to stabilize the “pitching grip” conformation of PL-I since the  
208 R599A mutant did not show any unfolding activity, similar to the PL-I mutation (**Fig. 2d**). In  
209 contrast, the pore loops in the D2 domain of the nontranslocating structure (PDB ID: 7JY5) were  
210 mostly unstructured (**Fig. 2c**).

211 PL-I in the D1 ring interacted with the translocating peptide in the same fashion as that  
212 in the D2 ring, except that only four PL-I (chains B-E) were engaged and the three residues  
213 were K277, L278, and A279 (**Fig. 2a**). The “pitching grip” and hydrogen bonding pattern still  
214 existed, but the interaction was not as strong as that of the D2 ring since the average length of  
215 the hydrogen bonds was 3.9 Å in the D1 ring and 3.4 Å in the D2 ring. Two PL-II of the D1 ring  
216 (chains C and D) were involved in the interaction with the peptide by forming a hydrogen bond  
217 through H317 (**Fig. 2a**). Interestingly, H317 of chains B and C also stacked with W551 (PL-I of

218 D2) of chains D and E, respectively (**Fig. 2a**, red double arrow). This  $\pi$ - $\pi$  stacking might be  
219 involved in the coordination of two ATPase rings.

220 To further investigate the behavior of p97 with substrates of different sizes, we used a  
221 much smaller substrate, Ub<sub>6</sub> (**Extended Data Fig. 1c**), and collected a third dataset, p97-  
222 Npl4/Ufd1-Ub<sub>6</sub>-FOM (**Extended Data Fig. 4**). Again, three conformations of the D1 ring that  
223 were very similar to those of the p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-FOM dataset were resolved.  
224 Intriguingly, the density corresponding to the translocating peptide was resolved only in the D2  
225 ring (**Fig. 2e**). The D1 ring was essentially void of the translocating peptide despite adopting the  
226 same conformation. One possible explanation is that the D1 ring is engaged only when a  
227 “complicated” substrate such as Ub<sub>n</sub>-Eos is encountered.

228 We noticed that the D2 ring of the closed state is similar to one of the Cdc48 structures<sup>30</sup>.  
229 Both have five PL-I engaging with the translocating peptide. When the D2 rings from two  
230 structures were superimposed, it was obvious that the two rings of p97 are out of register, that is,  
231 the lowest D2 and D1 domains are not in the same chain (**Fig. 2f**), whereas in Cdc48, the two  
232 rings essentially formed a single “split washer” (**Fig. 2g**). This out-of-register feature is  
233 consistent with the asynchronous hydrolysis occurring in the D1 and D2 rings.

234

### 235 **N- and C-terminal tails and the linker between D1 and D2 rings**

236 In addition to the ATPase rings, some of the N- and C-terminal tails (**Fig. 1a**) of p97  
237 were also resolved in the cryo-EM maps. Both the resolved N-terminal (L12 to R22) and C-  
238 terminal (G767-S775) tails interacted with the neighboring subunit in a counterclockwise manner  
239 if viewed from the top (N-terminal tail, **Fig. 3a**) or a clockwise manner if viewed from the bottom  
240 (C-terminal tail, **Fig. 3c**). The N-terminal tail interacted with an acidic patch in the  $\alpha$  subunit of  
241 the D1 domain (**Fig. 3b**). The C-terminal tail interacted with a groove in the  $\alpha$  subunit of the D2  
242 domain. Such interactions have not been described before and may play important roles in the  
243 coordination between different chains. Truncations of either the N- or C-terminal tails greatly

244 affected the unfolding activity of p97 (**Fig. 3f**). The linker between the D1 and D2 rings was  
245 resolved for chains B-E. Compared to the structure of nontranslocating p97 (PDB ID: 7JY5), a  
246 19 Å shift of L464 was observed (**Fig. 3e**). In the translocating structure, L464 interacted with  
247 A569 in the D2 domain, which contributed to the relative twist of the D2 ring (**Fig. 1e**). The  
248 L464A mutation decreased the unfolding activity of p97 (**Fig. 3f**). Notably, the N- and C-terminal  
249 tails and the linker regions are less conserved between human p97 and yeast Cdc48, which  
250 might contribute to the different conformations of the ATPase rings.

251

### 252 **NMS-873 inhibits the translocation by locking the ISS motif**

253 Inhibition of p97 has emerged as a promising strategy in anticancer and antiviral studies<sup>8</sup>.  
254 NMS-873, the first discovered noncompetitive inhibitor of p97 (**Fig. 4a**), was recently  
255 characterized as a candidate for the treatment of cancers, neurodegenerative diseases, and  
256 viral infections<sup>22-24</sup>. However, the mechanism of inhibition remained unclear. We introduced  
257 NMS-873 at saturation (80 μM) after triggering ATP hydrolysis and substrate translocation (**Fig.**  
258 **4b**). Two datasets were collected using Ub<sub>n</sub>-Eos and Ub<sub>6</sub> as the substrate. A single map was  
259 obtained from each dataset with overall resolutions of 2.4 Å (Ub<sub>6</sub>, **Extended Data Fig. 8**) and  
260 2.8 Å (Ub<sub>n</sub>-Eos, **Extended Data Fig. 9**). The two maps are essentially identical; therefore, only  
261 the map with the higher resolution is shown (**Fig. 4c**). NMS-873 binds at a cryptic groove next to  
262 the ISS motif of the D2 domain (**Fig. 4d**) and is surrounded by many hydrophobic residues (**Fig.**  
263 **4e**). Through the interaction with the alkyl chain of K615, NMS-873 locked the ISS motif and  
264 prevented the essential conformational change discovered in the translocating structures (**Fig.**  
265 **4f**). As a result, no translocating peptides were found in the central pore, and the structure was  
266 6-fold symmetric, although a substrate was present, and ATP hydrolysis was triggered before  
267 adding NMS-873.

268 Compared to the ATPγS-bound nontranslocating structure (PDB ID: 7JY5), the relative  
269 positions of the ATPase rings in the NMS-873-bound structure are similar (**Extended Data Fig.**

270 **5b**). The bottom opening of the D2 ring was expanded, which is similar to that of the ADP-bound  
271 structures<sup>13</sup>, although ATP was engaged (**Extended Data Fig. 5c**). The pore loops in the D2  
272 domain of the NMS-873-bound structure were resolved but retracted from the pore compared to  
273 the translocating structure (**Extended Data Fig. 5e**). The smaller angle between the  $\alpha/\beta$  and the  
274  $\alpha$  subdomains suggested that it is more similar to an ADP-bound state (**Extended Data Fig. 5d**).  
275 Indeed, superimposing the NMS-873-bound structure with another inhibitor-bound structure  
276 (UPCDC30245, PDB ID: 5FTJ<sup>13</sup>) showed surprising similarities, including the conformations of  
277 pore loops and a shared binding pocket of the two inhibitors in the D2 domain (**Extended Data**  
278 **Figs. 5f and 5g**). The difference is that the UPCDC30245-bound structure was determined in  
279 the presence of ADP without a cofactor and a substrate, and the compound was not fully  
280 resolved in the cryo-EM map<sup>13</sup>. Importantly, the interaction between K615 and the biphenyl  
281 group of NMS-873, which essentially locks the ISS motif, does not occur in the UPCDC30245-  
282 bound structure (**Fig. 4f and Extended Data Fig. 5g**). Previous studies found that  
283 UPCDC30245, a phenyl indole amide-based allosteric inhibitor, is an uncompetitive inhibitor and  
284 binds only in the presence of ADP, whereas triazole-based NMS-873 is a noncompetitive  
285 inhibitor and can bind in the absence of nucleotides<sup>21</sup>. This locking mechanism of NMS-873  
286 through K615 might be the key for noncompetitive allosteric inhibition.

287

## 288 **Conformational states of Npl4 revealed by NMS-873 at a substoichiometric concentration**

289 We further discovered that NMS-873 did not fully inhibit the unfolding activity of p97 at a  
290 substoichiometric concentration (6 equivalents (eq) is the stoichiometric concentration, **Fig. 4g**).  
291 On the reasoning that intermediate structures could be captured using NMS-873 as a modulator,  
292 a dataset was collected following the same protocol using Ub<sub>n</sub>-Eos as the substrate and in the  
293 presence of 10  $\mu$ M NMS-873 (~0.2 eq, **Fig. 5a**). As expected, multiple intermediate structures  
294 were resolved after 3D classification (**Extended Data Fig. 10**). Two out of six maps (~11%  
295 particles) are in the nontranslocating state, with flat and symmetric ATPase rings and no density

296 for a translocating peptide (**Fig. 5c**). One of the nontranslocating maps (Class 1, ~8% particles)  
297 showed the density of NMS-873 (**Fig. 5c**, top) in all six binding pockets, suggesting that the  
298 binding of NMS-873 is highly cooperative. The cofactor Npl4 was resolved in four out of six  
299 maps (**Extended Data Fig. 10**). Both nontranslocating maps showed density for Npl4, with  
300 either one or two of its zinc finger motifs (ZF1 and ZF2, **Fig. 5b**) binding on top of the D1 ring  
301 (**Fig. 5c**). Such seesaw conformations of Npl4 have been described in a previous study<sup>26</sup>. The  
302 four translocating structures all had spiral ATPase rings and a translocating peptide similar to  
303 the conformation of the closed state (**Extended Data Fig. 10**). Two maps (class 5 and class 6)  
304 had very poor densities of Npl4 and differed in the D1 ring in a similar way to class 1 and class 3  
305 of the p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-FOM dataset. The other two maps showed density for Npl4, but  
306 with its zinc finger motifs interacting with different chains (**Fig. 5d**), suggesting a rotation of Npl4  
307 on top of the D1 ring. Although the resolution of Npl4 is not sufficient for atomic model building,  
308 a trace density connected to the translocating peptide can be seen to be engaged in a groove of  
309 Npl4 (**Fig. 5d**, top), which is reminiscent of a substrate processing complex structure of Cdc48<sup>19</sup>.  
310

311 **DISCUSSION**

312 Here, we report the cryo-EM structures of human p97 in several working states, with a  
313 translocating peptide going through the central pore. Together, the structures revealed “power  
314 stroke”-like conformational changes in both the D1 and D2 rings. Surprisingly, the two AAA  
315 domains undergoing power stroke motion in each ring were not from the same chain, which  
316 seemed to be a unique feature of human p97 and was not observed for Cdc48 and other Type-II  
317 AAA proteins<sup>15,16,19,30,32,33</sup>. The unusual structural feature corresponds to the asynchronous  
318 hydrolysis taking place in the two ATPase rings (**Fig. 1e**). Regarding translocation, the D2 ring  
319 seemed to play a more important role by tightly interacting with the peptide through backbone  
320 hydrogen bonds. The D1 ring was engaged when encountering a much larger substrate.  
321 Previous biochemical studies have shown that the D2 ring of p97 had higher ATPase activity  
322 and provided the driving force for translocation, which is consistent with our structures<sup>34</sup>. The  
323 structures of Cdc48 also showed fewer interactions between the translocating peptide and the  
324 pore loops of the D1 ring<sup>19</sup>, further supporting this hypothesis. Although the structures strongly  
325 support a sequential hydrolysis model<sup>35</sup>, it is not clear whether the power strokes in the D1 and  
326 D2 rings take place concurrently. Multiple structures from a single dataset are needed to  
327 address this question. In this study, the motions of the D1 and D2 rings were resolved from two  
328 datasets, one using CHAPSO and the other using FOM as the detergent to fix the orientation  
329 preference. CHAPSO required a much higher concentration of the complex than FOM (8x) to  
330 keep the samples in the hole but seemed to preserve the complex better and yielded more  
331 particles with Npl4. Since the open state is a minor conformation (7% of the total particles,  
332 **Extended Data Fig. 2**), the higher concentration of the CHAPSO dataset may have contributed  
333 to its discovery.

334 The cryo-EM structures of human p97 in complex with NMS-873 revealed the  
335 mechanism of allosteric inhibition by locking the ISS motif in the D2 domain, which together with  
336 the ISS motif in the D1 domain played critical roles in forming the compressed ATPase rings

337 essential for substrate translocation (**Fig. 1f**). Targeting the ISS motif of p97, therefore, may  
338 serve as a potential strategy for the development of new inhibitors.

339 Multiple structures in the presence of NMS-873 at a substoichiometric concentration  
340 suggested that Npl4 may play a critical role in the initiation of translocation by unfolding the  
341 ubiquitin chain and threading it into the central pore through a seesaw motion. The pore loops in  
342 the D1 and D2 rings catch the thread-in peptide, and the two rings are compressed to spiral  
343 conformations. Following sequential ATP hydrolysis and power stroke motions circulating in  
344 both rings, the peptide in the pore is translocated downward. Npl4 might be unnecessary once  
345 the translocation starts.

346 Mutations in p97 have been linked to MSP<sup>6,36</sup>. Structures of p97 in working states  
347 provided crucial insights into the consequences of the mutations (**Extended Data Table 3**,  
348 **Supplemental Movie 3**). The resolutions of the cryo-EM maps in this study are among the  
349 highest of type II AAA proteins<sup>15,17,19,30,33,37</sup>, allowing a comprehensive understanding of  
350 substrate processing and allosteric inhibition of human p97 and shedding light on the  
351 mechanism of other type II AAA proteins.

352

353 **METHODS**

354 **Protein expression and purification**

355 Wildtype human p97, human p97 mutants, Npl4/Ufd1, His<sub>6</sub>-Ub<sup>G76V</sup>-Ub<sup>G76V</sup>-mEos3.2 (Ub-  
356 Eos), human UBA1, Ube25k and gp78RING-Ube2g2 were purified as previously  
357 described<sup>26,31,38</sup>. Briefly, all proteins were expressed in *E. coli* BL21(DE3) cells and purified  
358 through Ni-NTA resin at 4 °C. All purified proteins were further buffer-exchanged to the Storage  
359 Buffer containing 50 mM HEPES, pH 8.0, 150 mM NaCl, 1 mM MgCl<sub>2</sub>, 0.5 mM tris(2-  
360 carboxyethyl)phosphine (TCEP) before snap freezing.

361

362 **Preparation of polyubiquitinated Ub-Eos and polyubiquitin chain**

363 For cryo-EM studies, His-tagged Ub-Eos was directly used for polyubiquitination. For the  
364 substrate unfolding assay, Ub-Eos was first irradiated under LED UV light (385-395 nm,  
365 uvBeast V2) for 1 hour at 4 °C to induce the photoconversion of mEos3.2, followed by  
366 polyubiquitination. The polyubiquitination reaction was performed as previously described<sup>31</sup>.  
367 Briefly, 20 μM Ub-Eos was mixed with 1 μM UBA1, 20 μM gp78RING-Ube2g2, and 500 μM  
368 ubiquitin in the Ubiquitination Buffer containing 20 mM Hepes, pH 7.4, 150mM KCl, 10 mM ATP,  
369 and 10 mM MgCl<sub>2</sub>. After incubation at 37 °C overnight, the mixture was incubated with Ni-NTA  
370 resin to remove free ubiquitin chains. The elution was further separated using a Superdex 200  
371 (GE Healthcare) size-exclusion column equilibrated in the Storage Buffer. Polyubiquitinated Ub-  
372 Eos (Ub<sub>n</sub>-Eos) with longer ubiquitin chains (estimated over 10 ubiquitin subunits) was collected  
373 and flash frozen for the substrate unfolding assay.

374 K48-linked polyubiquitin chains were assembled by mixing 1 μM UBA1, 10 μM Ube25k,  
375 and 1 mM ubiquitin in the Ubiquitination Buffer at 37 °C for 4 hours. The reaction mixture was  
376 then diluted 10 folds with 50 mM NaOAc, pH 4.5, and separated by a Mono S cation exchange  
377 column. The corresponding peak for hexa-ubiquitin chain (Ub<sub>6</sub>) was collected and further



378 purified with a Superdex 75 (GE Healthcare) size-exclusion column equilibrated in the Storage  
379 Buffer.

380

### 381 **Assembly of substrate-engaged p97 complex**

382 p97-Npl4/Ufd1 complex was assembled as previously described<sup>26</sup>. A p97 mutant bearing  
383 A232E and E578Q mutations was used in order to decrease the heterogeneity of N domains  
384 and reduce the unfolding activity of the complex. Two-fold molar excess of Ub<sub>6</sub> or Ub<sub>n</sub>-Eos was  
385 added to the p97-Npl4/Ufd1 complex, followed by gel filtration using a Superose 6 column (GE  
386 Healthcare) equilibrated in the Storage Buffer (**Extended Data Fig. 1b and 1c**). The assembled  
387 substrate-engaged p97 complex was flash frozen in liquid nitrogen for structural studies. No  
388 nucleotide was supplemented during the assembly.

389

### 390 **Specimen preparation for single-particle cryo-EM**

391 All samples for cryo-EM were prepared as previously described<sup>26</sup>, with the following  
392 modifications. Either fluorinated octyl maltoside (FOM) or CHAPSO was used to relieve the  
393 preferred orientations instead of IGEPAL CA-630. The complex was concentrated to ~2.5  
394 mg/mL followed by incubation with 5 mM ATP at room temperature for 5 minutes before adding  
395 FOM (final concentration 0.01% v/v, Fig. 1b). Glow discharged Quantifoil Cu 1.2/1.3 grids were  
396 used for FOM supplemented samples. Alternatively, the samples were concentrated to  
397 ~20mg/mL followed by incubation with 5 mM ATP at room temperature for 5 minutes before  
398 adding CHAPSO (final concentration 4 mM, Fig. 1b). Non-glow-discharged Quantifoil Cu 1.2/1.3  
399 grids were used for CHAPSO supplemented samples. In both cases, 3.5 µL sample was applied  
400 to the grid and was blotted for 1 second using standard Vitrobot filter paper (Ted Pella, 47000-  
401 100) before plunge freezing in liquid ethane. For substrate-engaged p97-Npl4/Ufd1 complex in  
402 the presence of NMS-873, besides the aforementioned procedures, NMS-873 was  
403 supplemented right after the incubation with ATP at either 10 µM or 80 µM final concentration.

404 The samples were incubated for another 30 min at room temperature before adding the  
405 detergents and plunge freezing (Fig. 4b and 5a).

406

#### 407 **Data collection for single-particle cryo-EM**

408 Data collection was performed either in Advanced Electron Microscopy Facility at the  
409 University of Chicago or National Cryo-Electron Microscopy Facility at the National Cancer  
410 Institute. All datasets were acquired as movie stacks with a Titan Krios electron microscope  
411 operating at 300 kV, equipped with either a Gatan K2 Summit or K3 direct detector camera. A  
412 single stack typically consists of 40 frames with a total exposure around 50 electrons/Å<sup>2</sup>. The  
413 defocus range was set at -1.0 to -2.5 μm. See **Extended Data Table 1** for the details.

414

#### 415 **Image processing**

416 Movie stacks were subjected to beam-induced motion correction using MotionCor2<sup>39</sup>.  
417 CTF parameters for each micrograph were determined using CTFFIND4<sup>40</sup>. Particle picking, two-  
418 and three-dimensional classifications, three-dimensional refinement, and local resolution  
419 estimation were performed in RELION-3<sup>41</sup>. Particle picking was performed by manually  
420 choosing ~2,000 particles and generating templates through reference free 2D classification,  
421 followed by automatic template based picking. False-positive particles or particles classified in  
422 poorly defined classes were discarded after 2D classification. The initial 3D classification was  
423 performed on a binned dataset with the previously reported p97 structures as the reference  
424 model<sup>26</sup>. The detailed data processing flows are shown in Extended Data Figs. 2, 3, 4, 8, 9, and  
425 10. To make sure that the 3D classification did not miss any major conformations, additional  
426 runs were performed with different number of classes (ranges from 3-8) and different  
427 regularization parameters (ranges from 2-6). Since we did not observe a dependence on the  
428 regularization parameter, the results from the default value (T=4) were shown in the figures.

429 Data processing statistics are summarized in **Extended Data Table 1**. Reported resolutions are  
430 based on Fourier shell correlation (FSC) using the FSC=0.143 criterion.

431

### 432 **Model building, refinement, and validation**

433 Model building was based on the existing cryo-EM structures of human p97<sup>26</sup> (PDB ID:  
434 7JY5). The models of individual domains (N, D1, and D2) were first docked into the cryo-EM  
435 maps as rigid bodies using UCSF Chimera<sup>42</sup> followed by further adjustment using COOT<sup>43</sup>. For  
436 well-resolved regions, sharpened maps were used and individual residues were manually  
437 adjusted and fit into the density. For flexible regions, unsharpened maps were used and  
438 individual secondary structure elements or subdomains were fit into the density as rigid bodies.  
439 A short  $\beta$  strand was automatically built into the density corresponding to the translocating  
440 peptide using COOT, followed by manual extension on either ends and real-space refinement  
441 until the all the density was covered. The final models were subjected to global refinement and  
442 minimization in real space using the real-space refinement module in Phenix<sup>44</sup>. Model validation  
443 was performed using the comprehensive validation tool in Phenix. The statistics of model  
444 refinement is shown in **Extended Data Table 2**.

445

### 446 **Substrate unfolding assay**

447 Substrate unfolding assay was performed as previously described<sup>26,31</sup>. Briefly, 20 nM  
448 photoconverted polyubiquitinated Ub-Eos was mixed with 400 nM p97 or p97 mutants and 500  
449 nM Npl4/Ufd1 in the Assay Buffer containing 50 mM Tris pH 7.4, 5 mM KCl, 20 mM MgCl<sub>2</sub>, 1  
450 mM EDTA, 0.5 mM TCEP, and 0.01% Triton. Proteins were pre-incubated in a 96-well plate  
451 (Costar 3694) for 10 minutes at 37 °C before initiating the reaction by supplementing the ATP  
452 regeneration mixture (5 mM ATP, 30 mM creatine phosphate, and 50  $\mu$ g/mL creatine  
453 phosphokinase). Fluorescence signal was monitored using a TECAN safire2 plate reader at 540  
454 nm excitation and 580 nm emission wavelengths with 30 seconds intervals for 60 min. Each

455 reaction condition was repeated three times. Background fluorescence was measured by mixing  
456 the same amount of substrate with 6 M guanidine-HCl and was subtracted from the average of  
457 the experimental groups. Normalized fluorescence was plotted using GraphPad Prism 8.4.2.  
458

459 **DATA AVAILABILITY**

460 Cryo-EM maps have been deposited in the Electron Microscopy Data Bank (EMDB)  
461 under the accession codes EMDB-23449 (p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-CHAPSO, Class 1), EMDB-  
462 23450 (p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-CHAPSO, Class 2), EMDB-23451 (p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-  
463 CHAPSO, Class 3), EMDB-23446 (p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-FOM, Class 1), EMDB-23447 (p97-  
464 Npl4/Ufd1-Ub<sub>n</sub>-Eos-FOM, Class 2), EMDB-23448 (p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-FOM, Class 3),  
465 EMDB-23443 (p97-Npl4/Ufd1-Ub<sub>6</sub>-FOM, Class 1), EMDB-23444 (p97-Npl4/Ufd1-Ub<sub>6</sub>-FOM,  
466 Class 2), EMDB-23445 (p97-Npl4/Ufd1-Ub<sub>6</sub>-FOM, Class 3), EMDB-23442 (p97-Npl4/Ufd1-Ub<sub>6</sub>-  
467 NMS-873-FOM), EMDB-23452 (p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-NMS-873-CHAPSO), EMDB-23453  
468 (p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-NMS-873(substoichiometric)-CHAPSO, Class 1), EMDB-23454 (p97-  
469 Npl4/Ufd1-Ub<sub>n</sub>-Eos-NMS-873(substoichiometric)-CHAPSO, Class 2), EMDB-23455 (p97-  
470 Npl4/Ufd1-Ub<sub>n</sub>-Eos-NMS-873(substoichiometric)-CHAPSO, Class 3), EMDB-23456 (p97-  
471 Npl4/Ufd1-Ub<sub>n</sub>-Eos-NMS-873(substoichiometric)-CHAPSO, Class 4), EMDB-23457 (p97-  
472 Npl4/Ufd1-Ub<sub>n</sub>-Eos-NMS-873(substoichiometric)-CHAPSO, Class 5), EMDB-23458 (p97-  
473 Npl4/Ufd1-Ub<sub>n</sub>-Eos-NMS-873(substoichiometric)-CHAPSO, Class 6). The atomic models have  
474 been deposited in the Protein Data Bank (PDB) under the accession codes 7LN5 (p97-  
475 Npl4/Ufd1-Ub<sub>n</sub>-Eos-CHAPSO, Class 1), 7LN6 (p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-CHAPSO, Class 2),  
476 7LN2 (p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-FOM, Class 1), 7LN3 (p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-FOM, Class 2),  
477 7LN4 (p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-FOM, Class 3), 7LMZ (p97-Npl4/Ufd1-Ub<sub>6</sub>-FOM, Class 1), 7LN0  
478 (p97-Npl4/Ufd1-Ub<sub>6</sub>-FOM, Class 2), 7LN1 (p97-Npl4/Ufd1-Ub<sub>6</sub>-FOM, Class 3), 7LMY (p97-  
479 Npl4/Ufd1-Ub<sub>6</sub>-NMS-873-FOM).

480

481 **ACKNOWLEDGEMENT**

482 Funding for this work was, in part, provided by the Catalyst Award from the Chicago  
483 Biomedical Consortium. This work was supported by Chicago Biomedical Consortium Catalyst  
484 Award C-086 to M.Z. We thank the National Key R&D Program of China (No.

485 2017YFA0505200), NSFC (91753205) for financial support. We thank staff at the National Cryo-  
486 Electron Microscopy Facility at the Frederick National Laboratory and the Advanced Electron  
487 Microscopy Facility at the University of Chicago for the help in cryo-EM data collection. This  
488 research was, in part, supported by the National Cancer Institute's National Cryo-EM Facility at  
489 the Frederick National Laboratory for Cancer Research under contract HSSN261200800001E.

490

#### 491 **AUTHOR CONTRIBUTIONS**

492 M.P. and M.Z. designed all the experiments and interpreted the results. M.P., Y.Y., H.A.,  
493 Q.Z., and Y.X. cloned, expressed, and purified all the complexes and carried out related  
494 biochemical characterizations. M.P., Y.Y., and M.Z. performed cryo-EM data collection and  
495 processing. M.Z., M.P., and L.L. wrote the paper. M.Z., L.L., and M.P. supervised the project.

496

#### 497 **COMPETING INTERESTS**

498 The authors declare no competing interests.

499

500

501


502

503

504

505 **FIGURE LEGENDS**

506 **FIGURE 1**



507

508

509


510

511 **Figure 1: Structures of human p97 in working states.**

512 **a**, Domain architecture of human p97. The color code of individual domains is used whenever  
513 possible. Pore loop residues in D1 and D2 domains are listed. **b**, Sample preparation  
514 procedures. Steps performed at 4 °C are in blue boxes. Steps performed at room temperature  
515 are in red boxes. **c and d**, Cryo-EM maps and models of human p97 engaged with a  
516 translocating peptide. The maps and models are aligned. Contour level: unsharpened map,  
517 0.015; sharpened map, 0.035. **c**, Open state. **d**, Closed state. **e**, Illustrations showing the  
518 arrangement of the D1 and D2 rings in the open and closed states, respectively. **f**, Magnified  
519 views of compressed ATP binding sites in the D1 and D2 rings. The corresponding ATP $\gamma$ S  
520 binding sites from the nontranslocating structure (PDB ID: 7JY5) are shown for comparison.  
521



522 **FIGURE 2**



523

524 **Figure 2: Interactions between the pore loops and the substrate.**

525 **a**, Interactions between the translocating peptide and the interacting pore loops in the D1 and

526 D2 rings. The density of the pore loops and the translocating peptide are shown as a gray mesh

527 and yellow surface, respectively. Contour level: 6.0 root-mean-square deviation (rmsd). The

528 closed state and PL-II of the D2 ring are shown in the insets. Hydrogen bonds between the pore

529 loops and the peptide are labeled with black dotted lines.  $\pi$ - $\pi$  interactions between H317 and


530 W551 are labeled with red double arrows. **b and c**, A comparison of the D2 domain in chain D

531 of the open state (panel **b**) and that of the nontranslocating structure (panel **c**, PDB ID: 7JY5).

532 The D2 domains are aligned. **d**, Substrate unfolding assay for the pore loop mutants of p97. The

533 error bands represent the standard deviation from triplicate experiments. **e**, Unsharpened cryo-  
534 EM map (class 1) of the p97-Npl4/Ufd1-Ub<sub>6</sub>-FOM dataset (**Extended Data Fig. 4**). The map is  
535 shown in a similar orientation to **Fig. 1c and 1d**. Contour level: 0.015. **f and g**, A comparison of  
536 cryo-EM models of translocating structures of p97 (closed state, panel **f**) and Cdc48 (PDB ID:  
537 6OPC, panel **g**). The two models are aligned based on the D2 ring. The  $\alpha$ 2 helices immediately  
538 before PL-I in D1 and D2 domains are colored. The color code is the same as that in panel **a**.  
539

540 **FIGURE 3**



541

542

543 **Figure 3: N- and C-terminal tails and the linker between the D1 and D2 rings.**


544 **a**, Top view of the unsharpened cryo-EM map focused on the N and D1 domains (open state).

545 N-terminal tails are colored in red. Contour level: 0.015. **b**, A side view of the cryo-EM model of

546 the open state with the density of one N-terminal tail highlighted and magnified. Contour level:

547 6.0 rmsd. **c**, A bottom view of the unsharpened cryo-EM map focused on the D2 ring (open  
548 state). C-terminal tails are shown in red. Contour level: 0.015. **d**, A side view of the cryo-EM  
549 model of the open state with the density of one C-terminal tail highlighted and magnified.  
550 Contour level: 6.0 rmsd. **e**, A comparison of the D1-D2 linker in chain D of the open state and  
551 that of the nontranslocating structure (PDB ID: 7JY5). The D2 domains are aligned. **f**, Substrate  
552 unfolding assay for tail and linker mutants of p97. The error bands represent the standard  
553 deviation from triplicate experiments.  
554

555 **FIGURE 4**



556

557 **Figure 4: NMS-873 inhibits translocation by locking the ISS motif.**


558 **a**, Chemical structure of NMS-873. **b**, Sample preparation procedures. Steps performed at 4 °C

559 are in blue boxes. Steps performed at room temperature are in red boxes. **c**, Cryo-EM maps

560 and models of human p97 in complex with NMS-873. The maps and models are aligned.

561 Contour level: unsharpened map, 0.018; sharpened map, 0.052. **d**, D2 domain of the complex  
562 structure in panel **c**, with the NMS-873 binding site zoomed in. The density of NMS-873 and the  
563 interacting residues are shown as magenta and gray mesh, respectively. Contour level: 6.0  
564 rmsd. **e**, A different view of the NMS-873 binding site, with side chains of interacting residues  
565 shown. Contour level: 6.0 rmsd. **f**, A comparison of nucleotide binding sites in NMS-873 bound,  
566 translocating (chain D in open state), and nontranslocating (PDB ID: 7JY5) structures. The  
567 bottom D2 domains (green, salmon, and gray) are aligned. **g**, Substrate unfolding assay for  
568 wild-type p97 in the presence of different concentrations of NMS-873. One p97 hexamer can  
569 bind 6 equivalents (eq) of NMS-873.  
570

571 **FIGURE 5**



572

573 **Figure 5: Conformational states of Npl4 in the presence of NMS873 at a**

574 **substoichiometric concentration.**

575 **a**, Sample preparation procedures. Steps performed at 4 °C are in blue boxes. Steps performed

576 at room temperature are in red boxes. **b**, Domain architecture of human Npl4. The color code of

577 the individual motifs are the same as that in panels **c** and **d**. Dotted parts are not resolved in the

578 cryo-EM maps. **c**, Two cryo-EM maps in nontranslocating states resolved from the dataset

579 (**Extended Data Fig. 10**), one bound with NMS-873 (top). **d**, Two cryo-EM maps in


580 translocating states resolved from the dataset. Different positions of zinc finger motifs of Npl4

581 are illustrated in the insets.

582

583 EXTENDED DATA FIGURES

584 EXTENDED DATA FIGURE 1



585

586 **Extended Data Figure 1: Substrate unfolding activity of various p97 mutants and the**  
587 **purification of cofactor- and substrate-engaged p97 complexes.**

588 **a**, Substrate unfolding assay for wild-type (WT) p97 and various mutations. E305Q and E578Q

589 are the two Walker B mutations in the D1 and D2 domains, respectively. A232E is a disease


590 mutation found in multisystem proteinopathy (MSP)<sup>27,31</sup>. **b**, Gel filtration chromatogram and

591 SDS-PAGE gel of the p97<sup>A232E/E578Q</sup>-Npl4/Ufd1-Ub<sub>n</sub>-Eos complex. **c**, Gel filtration chromatogram

592 and SDS-PAGE gel of the p97<sup>A232E/E578Q</sup>-Npl4/Ufd1-Ub<sub>n</sub>-Eos complex.



593 EXTENDED DATA FIGURE 2




595 **Extended Data Figure 2: Single-particle cryo-EM analyses for the p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-**  
596 **CHAPSO dataset.**

597 **a**, The workflow of data processing. The dataset was subjected to particle selection, 2D  
598 classification, and multiple rounds of 3D classification. A representative micrograph (scale bar  
599 corresponds to 50 nm) and representative 2D class averages are shown. Three classes were  
600 resolved from the dataset, including class 1 (closed state), class 2 (open state), and class 3  
601 (similar to the closed state but with the Npl4 density). The distributions of the Euler angles for  
602 each reconstruction are shown below the maps. **b**, Fourier shell correlation (FSC) curves of the  
603 masked maps after Relion postprocessing. The resolutions were determined by the FSC=0.143  
604 criterion. The model vs. map FSC curves are also shown for class 1 and class 2 (red). **c**, Local  
605 resolutions of the maps calculated using Relion.

606

607 EXTENDED DATA FIGURE 3




609 **Extended Data Figure 3: Single-particle cryo-EM analyses for the p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-**  
610 **FOM dataset.**

611 **a**, The workflow of data processing. The dataset was subjected to particle selection, 2D  
612 classification, and multiple rounds of 3D classification. A representative micrograph (scale bar  
613 corresponds to 50 nm) and representative 2D class averages are shown. Three classes were  
614 resolved from the dataset. The distributions of the Euler angles for each reconstruction are  
615 shown below the maps. **b**, FSC curves of the masked maps after Relion postprocessing. The  
616 resolutions were determined by the FSC=0.143 criterion. The model vs. map FSC curves for  
617 each class are also shown. **c**, Local resolutions of the maps calculated using Relion.

618

619 EXTENDED DATA FIGURE 4




621 **Extended Data Figure 4: Single-particle cryo-EM analyses for the p97-Npl4/Ufd1-Ub<sub>6</sub>-FOM**  
622 **dataset.**

623 **a**, The workflow of data processing. The dataset was subjected to particle selection, 2D  
624 classification, and multiple rounds of 3D classification. A representative micrograph (scale bar  
625 corresponds to 50 nm) and representative 2D class averages are shown. Three classes were  
626 resolved from the dataset. The distributions of the Euler angles for each reconstruction are  
627 shown below the maps. **b**, FSC curves of the masked maps after Relion postprocessing. The  
628 resolutions were determined by the FSC=0.143 criterion. The model vs. map FSC curves for  
629 each class are also shown. **c**, Local resolutions of the maps calculated using Relion.

630

631

632 **EXTENDED DATA FIGURE 5**



633

634 **Extended Data Figure 5: Comparison of various p97 structures.**


635 **a**, Unrolling of the open (top row) and closed (bottom row) states of p97. The lateral and vertical

636 movement of D2 domains can be visualized. The positions of pore loops are marked with solid

637 dots. Unresolved pore loops are marked by open circles. **b**, Unrolling of the ATP $\gamma$ S-bound  
638 nontranslocating structure (PDB ID: 7JY5) and NMS-873-bound structure. Only one chain of  
639 each structure is shown since both structures are sixfold symmetric. **c**, A superimposition of  
640 7JY5- and NMS-873-bound structures. Left: a top view of the N and D1 domains; Right: a  
641 bottom view of the D2 ring. The opening of the D2 ring is marked by a dotted hexagon. Panels **a**,  
642 **b**, and **c** share the same color code. **d**, A comparison of the D2 domain in the NMS-873-bound  
643 structure and that in chain D of the open state. The superimposition is based on the  $\alpha/\beta$   
644 subdomain. **e**, Magnified views of the dotted box in panel **d**, showing the conformations of the  
645 PL-I, PL-II, and ISS motifs. **f**, A comparison of the D2 domain in NMS-873- and UPCDC30245  
646 (PDB ID: 5FTJ)-bound structures. The superimposition is based on the  $\alpha/\beta$  subdomain. **g**,  
647 Magnified views of the dotted box in panel **f**, showing the binding sites of the compounds and  
648 the conformations of the ISS motif.  
649



650 **EXTENDED DATA FIGURE 6**




651

652 **Extended Data Figure 6: The power stroke motion and the nucleotide binding sites of the**  
653 **D2 domains.**

654 **a**, A superimposition of the open and closed state structures, with two D2 domains (chain A and  
655 chain F) magnified. The relative positions of the D2 domains in chain A and chain F can be  
656 visualized. **b**, Top views of the D2 ring in the open and closed states, highlighting chain A, chain  
657 F, and the ISS motifs. **c**, Superimpositions of all D2 domains in the open and closed states  
658 based on the  $\alpha/\beta$  subdomain. The directions of  $\alpha 7$  helices are highlighted by dotted lines for  
659 comparison (dark blue, chain A; light blue, chain F; and gray, other chains). **d**, Individual  
660 nucleotide binding sites of the D2 domains in the open and closed states. Blue mesh:  
661 unsharpened map at contour level; Gray mesh: sharpened map at contour level.;

662

663 **EXTENDED DATA FIGURE 7**




664

665

666 **Extended Data Figure 7: The power stroke motion and the nucleotide binding sites of the**  
667 **D1 domains.**

668 **a**, A superimposition of three structures (classes 1, 2, and 3) from the p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-  
669 FOM dataset, with two D1 domains (chain A and chain F) magnified. The relative positions of  
670 the D1 domains in chain A and chain F can be visualized. **b**, Top views of the D1 ring in the  
671 three classes, highlighting chain A, chain F, and the ISS motifs. **c**, Superimpositions of all D1  
672 domains in class 1 and class 3 based on the  $\alpha/\beta$  subdomain. The directions of  $\alpha 7$  helices are  
673 highlighted by dotted lines for comparison (dark blue, chain A; light blue, chain F; and gray,  
674 other chains). **d**, Individual nucleotide binding sites of the D1 domains in class 1 and class 3.  
675 Blue mesh: Unsharpened map at contour level; Gray mesh: sharpened map at contour level.;  
676

677 EXTENDED DATA FIGURE 8




679 **Extended Data Figure 8: Single-particle cryo-EM analyses for the p97-Npl4/Ufd1-Ub<sub>6</sub>**  
680 **complex in the presence of 80  $\mu$ M NMS-873.**

681 **a**, The workflow of data processing. The dataset was subjected to particle selection, 2D  
682 classification, and multiple rounds of 3D classification. A representative micrograph (scale bar  
683 corresponds to 50 nm) and representative 2D class averages are shown. A single class was  
684 resolved from the dataset. The distribution of the Euler angles is shown next to the map. **b**, The  
685 FSC curve of the masked map after Relion postprocessing. The resolution was determined by  
686 the FSC=0.143 criterion. The model vs. map FSC curve is also shown. **c**, Local resolution of the  
687 map calculated using Relion.

688

689

690 EXTENDED DATA FIGURE 9



692 **Extended Data Figure 9: Single-particle cryo-EM analyses for the p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos**  
693 **complex in the presence of 80 μM NMS-873.**

694 **a**, The workflow of data processing. The dataset was subjected to particle selection, 2D  
695 classification, and multiple rounds of 3D classification. A representative micrograph (scale bar  
696 corresponds to 50 nm) and representative 2D class averages are shown. A single class was  
697 resolved from the dataset. The distribution of the Euler angles is shown next to the map. **b**, The  
698 FSC curve of the masked map after Relion postprocessing. The resolution was determined by  
699 the FSC=0.143 criterion. **c**, Local resolution of the map calculated using Relion.


700

701

702



703 **EXTENDED DATA FIGURE 10:**



705 **Extended Data Figure 10: Single-particle cryo-EM analyses for the p97-Npl4/Ufd1-Ub<sub>n</sub>-**

706 **Eos complex in the presence of 10  $\mu$ M NMS-873.**

707 **a**, The workflow of data processing. The dataset was subjected to particle selection, 2D  
708 classification, and multiple rounds of 3D classification. A representative micrograph (scale bar  
709 corresponds to 50 nm) and representative 2D class averages are shown. Six classes were  
710 resolved from the dataset, including two in nontranslocating states (Class 1 and Class 2) and  
711 four in translocating states (Class 3 through Class 6). The distributions of the Euler angles for  
712 each reconstruction are shown next to the maps. **b**, FSC curves of the masked maps after  
713 Relion postprocessing. The resolutions were determined by the FSC=0.143 criterion. **c**, Local  
714 resolutions of the maps calculated using Relion.

715

716

717

718

719 **EXTENDED DATA TABLE 1: Statistics of cryo-EM data collection and processing**

	<b>p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos</b>			<b>p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos</b>		
Detergent	CHAPSO (4 mM)			FOM (0.001%)		
Microscope	Krios (UChicago)			Krios (NCI)		
Magnification	81,000			81,000		
Voltage (kV)	300			300		
Spherical aberration (mm)	2.7			2.7		
Detector	K3			K3		
Camera mode	Super resolution counting			Super resolution counting		
Exposure rate (e <sup>-</sup> /pixel/s)	15			15		
Total exposure (e <sup>-</sup> /Å <sup>2</sup> )	50			50		
Defocus range (μm)	-1.0 to -2.5			-1.0 to -2.5		
Pixel size (Å)	1.063			1.0794		
Mode of data collection	Image shift			Image shift		
Energy filter	20 eV slit			20 eV slit		
Software for data collection	EPU			Latitude S		
Number of micrographs	2,060			5,235		
Symmetry imposed	C1			C1		
Box size (pixel)	320			320		
Initial particle images (no.)	672,284			2,845,403		
Particle images for 3D (no.)	588,832			2,697,259		
	Class 1	Class 2	Class 3	Class 1	Class 2	Class 3
Final particle images (no.)	215,530	41,239	49,294	72,646	256,471	723,840
Map resolution, masked (Å)	3.09	3.58	3.77	3.63	3.45	3.02
B-factor estimated (Å <sup>2</sup> )	79.7	79.7	80.3	97.6	109	96.8
EMD accession code	23449	23450	23451	23446	23447	23448

720

	<b>p97-Npl4/Ufd1-Ub<sub>6</sub></b>		
Detergent	FOM (0.001%)		
Microscope	Krios (UChicago)		
Magnification	81,000		
Voltage (kV)	300		
Spherical aberration (mm)	2.7		
Detector	K3		
Camera mode	Super resolution counting		
Exposure rate (e <sup>-</sup> /pixel/s)	15		
Total exposure (e <sup>-</sup> /Å <sup>2</sup> )	50		
Defocus range (μm)	-1.0 to -2.5		
Pixel size (Å)	1.063		
Mode of data collection	Image shift		
Energy filter	20 eV slit		
Software for data collection	EPU		
Number of micrographs	1,718		
Symmetry imposed	C1		
Box size (pixel)	320		
Initial particle images (no.)	791,006		
Particle images for 3D (no.)	522,000		
	Class 1	Class 2	Class 3
Final particle images (no.)	118,214	117,776	98,051
Map resolution, masked (Å)	3.06	2.98	3.40
B-factor estimated (Å <sup>2</sup> )	69.1	64.7	77.3
EMD accession code	23443	23444	23445

721  
722

	<b>p97-Npl4/Ufd1-Ub<sub>6</sub>-NMS-873 (80 μM)</b>	<b>p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-NMS-873 (80 μM)</b>
Detergent	FOM (0.001%)	CHAPSO (4 mM)
Microscope	Krios (UChicago)	Krios (NCI)
Magnification	81,000	81,000
Voltage (kV)	300	300
Spherical aberration (mm)	2.7	2.7
Detector	K3	K3
Camera mode	Super resolution counting	Super resolution counting
Exposure rate (e <sup>-</sup> /pixel/s)	15	15
Total exposure (e <sup>-</sup> /Å <sup>2</sup> )	50	50
Defocus range (μm)	-1.0 to -2.5	-1.0 to -2.5
Pixel size (Å)	1.063	1.0794
Mode of data collection	Image shift	Image shift
Energy filter	20 eV slit	20 eV slit
Software for data collection	EPU	Latitude S
Number of micrographs	2,317	4,977
Symmetry imposed	C6	C6
Box size (pixel)	320	320
Initial particle images (no.)	782,499	1,266,504
Particle images for 3D (no.)	706,537	1,093,233
Final particle images (no.)	372,419	501,204
Map resolution, masked (Å)	2.41	2.87
B-factor estimated (Å <sup>2</sup> )	58.8	96.2
EMD accession code	23442	23452

723  
724

		<b>p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-NMS-873 (10 μM)</b>					
Detergent	CHAPSO (4 mM)						
Microscope	Krios (UChicago)						
Magnification	81,000						
Voltage (kV)	300						
Spherical aberration (mm)	2.7						
Detector	K3						
Camera mode	Super resolution counting						
Exposure rate (e <sup>-</sup> /pixel/s)	15						
Total exposure (e <sup>-</sup> /Å <sup>2</sup> )	50						
Defocus range (μm)	-1.0 to -2.5						
Pixel size (Å)	1.063						
Mode of data collection	Image shift						
Energy filter	20 eV slit						
Software for data collection	Latitude S						
Number of micrographs	3081						
Symmetry imposed	C1						
Box size (pixel)	320						
Initial particle images (no.)	1,052,005						
Particle images for 3D (no.)	1,048,794						
	Non-Translocating			Translocating			
	Class 1	Class 2	Class 3	Class 4	Class 5	Class 6	
Final particle images (no.)	83,317	29,966	74,774	58,762	137,997	78,523	
Map resolution, masked (Å)	3.69	6.07	3.58	4.25	3.47	3.65	
B-factor estimated (Å <sup>2</sup> )	105	198	93.0	129	91.7	92.0	
EMD accession code	23453	23454	23455	23456	23457	23458	

725  
726

727 **EXTENDED DATA TABLE 2: Statistics of cryo-EM model refinement and geometry**  
728

<b>Dataset: p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-CHAPSO</b>		
	<b>Class1 (Closed State)</b>	<b>Class2 (Open State)</b>
<b>Composition (#)</b>		
Chains	8	8
Atoms	35,051	35,072
Residues	Protein: 4,447	Protein: 4,456
Water	0	0
Ligands	MG: 7	MG: 7
	ADP: 5	ADP: 5
	ATP: 7	ATP: 7
<b>Bonds (RMSD)</b>		
Length (Å)	0.003	0.004
Angles (°)	0.617	0.673
MolProbity score	1.52	1.68
Clash score	9.95	10.93
<b>Ramachandran plot (%)</b>		
Outliers	0.00	0.02
Allowed	1.54	2.63
Favored	98.46	97.35
Rotamer outliers (%)	0.03	0.03
Cβ outliers (%)	0.00	0.00
<b>Peptide plane (%)</b>		
Cis proline/general	10.1/0.0	10.2/0.0
Twisted proline/general	0.0/0.0	0.0/0.0
CaBLAM outliers (%)	1.83	1.58
<b>ADP (B-factors)</b>		
Iso/Aniso (#)	35,051/0	35072/0
<b>min/max/mean</b>		
Protein	0.48/75.21/37.58	0.36/49.31/19.03
Ligand	11.67/65.09/33.22	2.26/41.30/13.85
PDB accession code	7LN5	7LN6

729  
730

<b>Dataset: p97-Npl4/Ufd1-Ub<sub>n</sub>-Eos-FOM</b>			
	<b>Class1</b>	<b>Class2</b>	<b>Class3</b>
<b>Composition (#)</b>			
Chains	8	8	8
Atoms	34,941	34,920	35,103
Residues	Protein: 4,433	Protein: 4,431	Protein: 4,455
Water	0	0	0
Ligands	MG: 7	MG: 7	MG: 8
	ADP: 5	ADP: 5	ADP: 4
	ATP: 7	ATP: 7	ATP: 8
<b>Bonds (RMSD)</b>			
Length (Å)	0.004	0.005	0.003
Angles (°)	0.651	0.674	0.604
MolProbity score	1.57	1.55	1.43
Clash score	11.31	10.70	7.52
<b>Ramachandran plot (%)</b>			
Outliers	0.07	0.07	0.00
Allowed	1.61	1.75	2.07
Favored	98.32	98.18	97.93
Rotamer outliers (%)	0.00	0.00	0.03
Cβ outliers (%)	0.00	0.00	0.00
<b>Peptide plane (%)</b>			
Cis proline/general	8.5/0.0	8.5/0.0	10.1/0.0
Twisted proline/general	0.0/0.0	0.0/0.0	0.0/0.0
CaBLAM outliers (%)	1.58	1.65	1.48
<b>ADP (B-factors)</b>			
Iso/Aniso (#)	34,941/0	34,920/0	35,103/0
min/max/mean			
Protein	0.79/73.39/37.41	0.45/71.85/36.71	0.39/86.71/50.32
Ligand	7.76/90.54/36.11	7.16/72.98/34.80	15.72/92.31/44.90
PDB accession code	7LN2	7LN3	7LN4

731  
732



<b>Dataset: p97-Npl4/Ufd1-Ub<sub>6</sub>-FOM</b>			
	<b>Class1</b>	<b>Class2</b>	<b>Class3</b>
<b>Composition (#)</b>			
Chains	8	8	8
Atoms	34,994	34,983	34,796
Residues	Protein: 4,434	Protein: 4,434	Protein:
Water	0	0	0
Ligands	MG: 8	MG: 7	MG: 7
	ADP: 4	ADP: 4	ADP: 5
	ATP: 8	ATP: 8	ATP: 7
<b>Bonds (RMSD)</b>			
Length (Å)	0.004	0.003	0.006
Angles (°)	0.654	0.646	0.759
MolProbity score	1.60	1.59	1.79
Clash score	12.30	11.95	14.43
<b>Ramachandran plot (%)</b>			
Outliers	0.09	0.05	0.05
Allowed	1.64	1.75	2.63
Favored	98.27	98.20	97.32
Rotamer outliers (%)	0.00	0.03	0.00
Cβ outliers (%)	0.00	0.00	0.00
<b>Peptide plane (%)</b>			
Cis proline/general	8.9/0.0	8.9/0.0	9.0/0.0
Twisted proline/general	0.0/0.0	0.0/0.0	0.0/0.0
CaBLAM outliers (%)	1.60	1.67	
<b>ADP (B-factors)</b>			
Iso/Aniso (#)	34,994/0	34,983/0	34,796/0
min/max/mean			
Protein	3.48/79.40/39.29	2.27/77.11/40.21	2.28/70.59/33.60
Ligand	12.21/68.94/37.64	8.22/74.08/36.83	11.82/52.39/30.60
PDB accession code	7LMZ	7LN0	7LN1

<b>Dataset: p97-Npl4/Ufd1-Ub<sub>6</sub>-NMS-873 (80 μM)</b>	
Composition (#)	
Chains	6
Atoms	35,646
Residues	Protein: 4,470
Water	0
Ligands	MG: 12
	NM3: 6 (NMS-873)
	ATP: 6
Bonds (RMSD)	
Length (Å)	0.003 (0)
Angles (°)	0.845 (3)
MolProbity score	1.79
Clash score	8.11
Ramachandran plot (%)	
Outliers	0.00
Allowed	2.71
Favored	97.29
Rotamer outliers (%)	1.89
Cβ outliers (%)	0.00
Peptide plane (%)	
Cis proline/general	10.0/0.0
Twisted proline/general	0.0/0.0
CaBLAM outliers (%)	0.95
ADP (B-factors)	
Iso/Aniso (#)	35,646/0
min/max/mean	
Protein	1.58/57.10/22.25
Ligand	2.92/28.45/15.85
PDB accession code	7LMY

734  
735

736 **EXTENDED DATA TABLE 3: A summary of human p97 disease mutations and potentially**  
737 **affected structures**  
738

<b>Disease Mutations</b>	<b>Potentially Affected Structures</b>
R93C/R93H, I114V, I151V	N domain structure
I126F, T127A, P137L, M158V, R159G/R159C/R159H, E185K	N-cofactor interaction
I27V, R95C/R95G/R95H, G97E, R155S/R155H/R155L, G156C/G156S, G157R, M158V, R159G/R159C/R159H, R191G/R191Q, L198W, G202W, A232E, T262A, K386E, N387H/N387S/N387T, A439S/A439P/A439G	N-D1 interaction
I206F	D1 nucleotide binding site
A232E	D1-D1 interaction
D395G	D1 domain structure
N401S	D1-D2 interaction
R487H, R662C	D2-D2 interaction
D592N	Pore loop II of D2 domain
N750S	C terminal tail

739

740 REFERENCES

- 741 1 Bodnar, N. & Rapoport, T. Toward an understanding of the Cdc48/p97 ATPase.  
742 *F1000Res* **6**, 1318 (2017).
- 743 2 Erzberger, J. P. & Berger, J. M. Evolutionary relationships and structural mechanisms of  
744 AAA+ proteins. *Annu. Rev. Biophys. Biomol. Struct.* **35**, 93-114 (2006).
- 745 3 Rabouille, C., Levine, T. P., Peters, J.-M. & Warren, G. An NSF-like ATPase, p97, and  
746 NSF mediate cisternal regrowth from mitotic golgi fragments. *Cell* **82**, 905-914 (1995).
- 747 4 van den Boom, J. & Meyer, H. VCP/p97-Mediated Unfolding as a Principle in Protein  
748 Homeostasis and Signaling. *Mol Cell*. **69**, 182-194 (2018).
- 749 5 Ye, Y. H., Tang, W. K., Zhang, T. & Xia, D. A Mighty "Protein Extractor" of the Cell:  
750 Structure and Function of the p97/CDC48 ATPase. *Front Mol Biosci.* **4**, 39 (2017).
- 751 6 Tang, W. K. & Xia, D. Mutations in the Human AAA+ Chaperone p97 and Related  
752 Diseases. *Front Mol Biosci.* **3**, 79 (2016).
- 753 7 Darwich, N. F. *et al.* Autosomal dominant VCP hypomorph mutation impairs  
754 disaggregation of PHF-tau. *Science* **370**, eaay8826 (2020).
- 755 8 Huryn, D. M., Kornfilt, D. J. P. & Wipf, P. p97: An Emerging Target for Cancer,  
756 Neurodegenerative Diseases, and Viral Infections. *J Med Chem.* **63**, 1892-1907 (2020).
- 757 9 Skrott, Z. *et al.* Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor  
758 NPL4. *Nature* **552**, 194-199 (2017).
- 759 10 Xia, D., Tang, W. K. & Ye, Y. Structure and function of the AAA+ ATPase p97/Cdc48p.  
760 *Gene* **583**, 64-77 (2016).
- 761 11 Huyton, T. *et al.* The crystal structure of murine p97/VCP at 3.6 angstrom. *J Struct Biol*  
762 **144**, 337-348 (2003).
- 763 12 Davies, J. M., Brunger, A. T. & Weis, W. I. Improved structures of full-length p97, an  
764 AAA ATPase: Implications for mechanisms of nucleotide-dependent conformational  
765 change. *Structure* **16**, 715-726 (2008).
- 766 13 Banerjee, S. *et al.* 2.3 Å resolution cryo-EM structure of human p97 and mechanism of  
767 allosteric inhibition. *Science* **351**, 871-875 (2016).
- 768 14 Zhang, X. *et al.* Structure of the AAA ATPase p97. *Mol Cell* **6**, 1473-1484 (2000).
- 769 15 Ripstein, Z. A., Huang, R., Augustyniak, R., Kay, L. E. & Rubinstein, J. L. Structure of a  
770 AAA+ unfoldase in the process of unfolding substrate. *Elife* **6**, e25754 (2017).
- 771 16 Puchades, C. *et al.* Structure of the mitochondrial inner membrane AAA+ protease  
772 YME1 gives insight into substrate processing. *Science* **358**, eaao0464 (2017).
- 773 17 Zhao, M. L. *et al.* Mechanistic insights into the recycling machine of the SNARE complex.  
774 *Nature* **518**, 61-67 (2015).
- 775 18 Cooney, I. *et al.* Structure of the Cdc48 segregase in the act of unfolding an authentic  
776 substrate. *Science* **365**, 502-505 (2019).
- 777 19 Twomey, E. C. *et al.* Substrate processing by the Cdc48 ATPase complex is initiated by  
778 ubiquitin unfolding. *Science* **365**, eaax1033 (2019).
- 779 20 Alvarez, C. *et al.* Allosteric Indole Amide Inhibitors of p97: Identification of a Novel Probe  
780 of the Ubiquitin Pathway. *Acs Med Chem Lett.* **7**, 182-187 (2016).
- 781 21 Magnaghi, P. *et al.* Covalent and allosteric inhibitors of the ATPase VCP/p97 induce  
782 cancer cell death. *Nat Chem Biol.* **9**, 548-556 (2013).
- 783 22 Zhang, T., Midshra, P., Hay, B. A., Chan, D. & Guo, M. Valosin-containing protein  
784 (VCP/p97) inhibitors relieve Mitofusin-dependent mitochondrial defects due to VCP  
785 disease mutants. *Elife* **6**, e17834 (2017).
- 786 23 Zhang, J. T. *et al.* Identification of NMS-873, an allosteric and specific p97 inhibitor, as a  
787 broad antiviral against both influenza A and B viruses. *Eur J Pharm Sci* **133**, 86-94  
788 (2019).

- 789 24 Bojkova, D. *et al.* Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.  
790 *Nature* **583**, 469-472 (2020).
- 791 25 Hao, Q. *et al.* A non-canonical role of the p97 complex in RIG-I antiviral signaling. *Embo*  
792 *J.* **34**, 2903-2920 (2015).
- 793 26 Pan, M. *et al.* Seesaw conformations of Npl4 in the human p97 complex and the  
794 inhibitory mechanism of a disulfiram derivative. *Nat Commun.* **12**, 121,  
795 doi:10.1038/s41467-020-20359-x (2021).
- 796 27 Blythe, E. E., Gates, S. N., Deshaies, R. J. & Martin, A. Multisystem Proteinopathy  
797 Mutations in VCP/p97 Increase NPLOC4.UFD1L Binding and Substrate Processing.  
798 *Structure* **27**, 1820-1829 (2019).
- 799 28 Bodnar, N. O. & Rapoport, T. A. Molecular Mechanism of Substrate Processing by the  
800 Cdc48 ATPase Complex. *Cell* **169**, 722-735 (2017).
- 801 29 Hanzelmann, P. & Schindelin, H. Structural Basis of ATP Hydrolysis and Intersubunit  
802 Signaling in the AAA+ ATPase p97. *Structure* **24**, 127-139 (2016).
- 803 30 Cooney, I. *et al.* Structure of the Cdc48 segregase in the act of unfolding an authentic  
804 substrate. *Science* **365**, 502-505 (2019).
- 805 31 Blythe, E. E., Olson, K. C., Chau, V. & Deshaies, R. J. Ubiquitin- and ATP-dependent  
806 unfoldase activity of P97/VCP center dot NPLOC4 center dot UFD1L is enhanced by a  
807 mutation that causes multisystem proteinopathy. *Proc Natl Acad Sci USA.* **114**, E4380-  
808 E4388 (2017).
- 809 32 Monroe, N., Han, H., Shen, P. S., Sundquist, W. I. & Hill, C. P. Structural basis of protein  
810 translocation by the Vps4-Vta1 AAA ATPase. *Elife* **6**, e24487 (2017).
- 811 33 Yokom, A. L. *et al.* Spiral architecture of the Hsp104 disaggregase reveals the basis for  
812 polypeptide translocation. *Nat Struct Mol Biol.* **23**, 830-837 (2016).
- 813 34 Song, C., Wang, Q. & Li, C.-C. H. ATPase Activity of p97-Valosin-containing Protein  
814 (VCP). *J Biol Chem.* **278**, 3648-3655 (2003).
- 815 35 Martin, A., Baker, T. A. & Sauer, R. T. Rebuilt AAA+ motors reveal operating principles  
816 for ATP-fuelled machines. *Nature* **437**, 1115-1120 (2005).
- 817 36 Meyer, H. & Weihl, C. C. The VCP/p97 system at a glance: connecting cellular function  
818 to disease pathogenesis. *J Cell Sci.* **127**, 3877-3883 (2014).
- 819 37 Tan, D., Blok, N. B., Rapoport, T. A. & Walz, T. Structures of the double-ring AAA  
820 ATPase Pex1/Pex6 involved in peroxisome biogenesis. *FEBS J.* **283**, 986-992 (2015).
- 821 38 Pickart, C. M. & Raasi, S. Controlled synthesis of polyubiquitin chains. *Methods Enzymol*  
822 **399**, 21-36 (2005).
- 823 39 Zheng, S. Q. *et al.* MotionCor2: anisotropic correction of beam-induced motion for  
824 improved cryo-electron microscopy. *Nat Methods* **14**, 331-332 (2017).
- 825 40 Mindell, J. A. & Grigorieff, N. Accurate determination of local defocus and specimen tilt in  
826 electron microscopy. *J Struct Biol* **142**, 334-347 (2003).
- 827 41 Zivanov, J. *et al.* New tools for automated high-resolution cryo-EM structure  
828 determination in RELION-3. *Elife* **7**, e42166 (2018).
- 829 42 Pettersen, E. F. *et al.* UCSF chimera - A visualization system for exploratory research  
830 and analysis. *J Comput Chem* **25**, 1605-1612 (2004).
- 831 43 Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta*  
832 *Crystallogr D* **60**, 2126-2132 (2004).
- 833 44 Adams, P. D. *et al.* PHENIX: a comprehensive Python-based system for macromolecular  
834 structure solution. *Acta Crystallogr D* **66**, 213-221 (2010).
- 835